Carisma Interest Expense vs Total Operating Expenses Analysis
| CARM Stock | 0.69 0.09 11.54% |
Carisma Therapeutics financial indicator trend analysis is way more than just evaluating Carisma Therapeutics prevailing accounting drivers to predict future trends. We encourage investors to analyze account correlations over time for multiple indicators to determine whether Carisma Therapeutics is a good investment. Please check the relationship between Carisma Therapeutics Interest Expense and its Total Operating Expenses accounts. Check out Trending Equities to better understand how to build diversified portfolios, which includes a position in Carisma Therapeutics. Also, note that the market value of any company could be closely tied with the direction of predictive economic indicators such as signals in metropolitan statistical area. To learn how to invest in Carisma Stock, please use our How to Invest in Carisma Therapeutics guide.
Interest Expense vs Total Operating Expenses
Interest Expense vs Total Operating Expenses Correlation Analysis
The overlapping area represents the amount of trend that can be explained by analyzing historical patterns of Carisma Therapeutics Interest Expense account and Total Operating Expenses. At this time, the significance of the direction appears to have very week relationship.
The correlation between Carisma Therapeutics' Interest Expense and Total Operating Expenses is 0.27. Overlapping area represents the amount of variation of Interest Expense that can explain the historical movement of Total Operating Expenses in the same time period over historical financial statements of Carisma Therapeutics, assuming nothing else is changed. The correlation between historical values of Carisma Therapeutics' Interest Expense and Total Operating Expenses is a relative statistical measure of the degree to which these accounts tend to move together. The correlation coefficient measures the extent to which Interest Expense of Carisma Therapeutics are associated (or correlated) with its Total Operating Expenses. Values of the correlation coefficient range from -1 to +1, where. The correlation of zero (0) is possible when Total Operating Expenses has no effect on the direction of Interest Expense i.e., Carisma Therapeutics' Interest Expense and Total Operating Expenses go up and down completely randomly.
Correlation Coefficient | 0.27 |
| Relationship Direction | Positive |
| Relationship Strength | Very Weak |
Interest Expense
The cost incurred by an entity for borrowed funds, including loans, bonds, or lines of credit.Total Operating Expenses
The total costs associated with the day-to-day operations of a business, excluding the cost of goods sold but including selling, general, and administrative expenses.Most indicators from Carisma Therapeutics' fundamental ratios are interrelated and interconnected. However, analyzing fundamental ratios indicators one by one will only give a small insight into Carisma Therapeutics current financial condition. On the other hand, looking into the entire matrix of fundamental ratios indicators, and analyzing their relationships over time can provide a more complete picture of the company financial strength now and in the future. Check out Trending Equities to better understand how to build diversified portfolios, which includes a position in Carisma Therapeutics. Also, note that the market value of any company could be closely tied with the direction of predictive economic indicators such as signals in metropolitan statistical area. To learn how to invest in Carisma Stock, please use our How to Invest in Carisma Therapeutics guide.As of the 11th of December 2024, Selling General Administrative is likely to grow to about 31 M, while Issuance Of Capital Stock is likely to drop about 24 M.
| 2021 | 2022 | 2023 | 2024 (projected) | Interest Expense | 8.3M | 3.1M | 1.9M | 2.0M | Depreciation And Amortization | 85K | 6.1M | 2.8M | 3.0M |
Carisma Therapeutics fundamental ratios Correlations
Click cells to compare fundamentals
Carisma Therapeutics Account Relationship Matchups
High Positive Relationship
High Negative Relationship
Carisma Therapeutics fundamental ratios Accounts
| 2019 | 2020 | 2021 | 2022 | 2023 | 2024 (projected) | ||
| Total Assets | 114.4M | 58.5M | 35.4M | 72.2M | 89.6M | 65.7M | |
| Other Current Liab | 6.6M | 1.6M | 4.5M | 10.9M | 6.7M | 4.1M | |
| Total Current Liabilities | 8.5M | 5.7M | 7.7M | 19.7M | 15.9M | 8.0M | |
| Total Stockholder Equity | (26.7M) | 35.8M | 11.6M | (49.3M) | 26.5M | 27.9M | |
| Property Plant And Equipment Net | 238K | 5.2M | 5.7M | 13.5M | 8.9M | 9.4M | |
| Net Debt | (48.1M) | (48.3M) | (25.9M) | 16.0M | (74.5M) | (70.8M) | |
| Retained Earnings | (293.5M) | (56.2M) | (97.0M) | (158.2M) | (245.1M) | (232.8M) | |
| Accounts Payable | 1.9M | 3.3M | 2.3M | 1.7M | 3.9M | 2.1M | |
| Cash | 48.1M | 51.8M | 28.6M | 24.2M | 77.6M | 81.5M | |
| Non Current Assets Total | 59.9M | 5.4M | 5.7M | 17.6M | 9.1M | 8.6M | |
| Non Currrent Assets Other | 196K | (78.5M) | (84.9M) | 4.1M | 146K | 153.3K | |
| Cash And Short Term Investments | 48.1M | 51.8M | 28.6M | 52.0M | 77.6M | 81.5M | |
| Common Stock Shares Outstanding | 4.5M | 5.9M | 9.1M | 106.4K | 33.5M | 35.2M | |
| Liabilities And Stockholders Equity | 114.4M | 58.5M | 35.4M | 72.2M | 89.6M | 65.7M | |
| Non Current Liabilities Total | 132.5M | 2.6M | 1.7M | 81.6M | 47.1M | 39.8M | |
| Other Current Assets | 6.3M | 1.3M | 1.2M | 2.6M | 2.9M | 1.5M | |
| Other Stockholder Equity | 266.8M | 199K | 619K | 1.2M | 271.6M | 285.2M | |
| Total Liab | 141.1M | 8.3M | 9.4M | 101.3M | 63.0M | 47.8M | |
| Total Current Assets | 54.4M | 53.1M | 29.8M | 54.6M | 80.5M | 84.5M | |
| Accumulated Other Comprehensive Income | (758K) | (140K) | (199K) | (41K) | (89.6M) | (85.1M) | |
| Common Stock | 77K | 107K | 140K | 199K | 40K | 56.4K |
Building efficient market-beating portfolios requires time, education, and a lot of computing power!
The Portfolio Architect is an AI-driven system that provides multiple benefits to our users by leveraging cutting-edge machine learning algorithms, statistical analysis, and predictive modeling to automate the process of asset selection and portfolio construction, saving time and reducing human error for individual and institutional investors.
Try AI Portfolio ArchitectCheck out Trending Equities to better understand how to build diversified portfolios, which includes a position in Carisma Therapeutics. Also, note that the market value of any company could be closely tied with the direction of predictive economic indicators such as signals in metropolitan statistical area. To learn how to invest in Carisma Stock, please use our How to Invest in Carisma Therapeutics guide.You can also try the Technical Analysis module to check basic technical indicators and analysis based on most latest market data.
Is Biotechnology space expected to grow? Or is there an opportunity to expand the business' product line in the future? Factors like these will boost the valuation of Carisma Therapeutics. If investors know Carisma will grow in the future, the company's valuation will be higher. The financial industry is built on trying to define current growth potential and future valuation accurately. All the valuation information about Carisma Therapeutics listed above have to be considered, but the key to understanding future value is determining which factors weigh more heavily than others.
Earnings Share (1.52) | Revenue Per Share 0.493 | Quarterly Revenue Growth (0.12) | Return On Assets (0.56) | Return On Equity (3.63) |
The market value of Carisma Therapeutics is measured differently than its book value, which is the value of Carisma that is recorded on the company's balance sheet. Investors also form their own opinion of Carisma Therapeutics' value that differs from its market value or its book value, called intrinsic value, which is Carisma Therapeutics' true underlying value. Investors use various methods to calculate intrinsic value and buy a stock when its market value falls below its intrinsic value. Because Carisma Therapeutics' market value can be influenced by many factors that don't directly affect Carisma Therapeutics' underlying business (such as a pandemic or basic market pessimism), market value can vary widely from intrinsic value.
Please note, there is a significant difference between Carisma Therapeutics' value and its price as these two are different measures arrived at by different means. Investors typically determine if Carisma Therapeutics is a good investment by looking at such factors as earnings, sales, fundamental and technical indicators, competition as well as analyst projections. However, Carisma Therapeutics' price is the amount at which it trades on the open market and represents the number that a seller and buyer find agreeable to each party.